ORIC Pharmaceuticals

CompanyUnited StatesFounded 2014

ORIC Pharmaceuticals develops one asset, preclinical (ORIC-259 in cancer). Mostly small molecule acting on CIP2A; based in the United States, founded in 2014.

1
Asset
Furthest stage: Preclinical; 1
Trial: 1
Signal

Pipeline

1

ORIC-259
Small molecule mRNA degrader targeting CIP2A
Preclinical, Small molecule, CIP2A, cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials1
Signals1
Similar companies6